China National Accord Medicines Corporation Ltd.
First Quarterly Report 2021
April 2021
Section I. Important Notes
Board of Directors and the Supervisory Committee of China National Accord
Medicines Corporation Ltd.(hereinafter referred to as the Company) and its
directors supervisors and senior executives should guarantee the reality
accuracy and completion of the quarterly report there are no any fictitious
statements misleading statements or important omissions carried in this report
and shall take legal responsibilities individual and/or joint.
All Directors are attended the Board Meeting for Quarterly Report deliberation.
Lin Zhaoxiong person in charge of the Company Gu Guolin person in charger
of accounting works and Wang Ying person in charger of accounting organ
(accounting officer) hereby confirm that the Financial Report of this Quarterly
Report is authentic accurate and complete.Section II. Company profile
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data
□Yes √No
Current Period Same period of last year
Changes of this period over
same period of last year
Operating income (RMB) 16049966325.75 12824196278.66 25.15%
Net profit attributable to shareholders of
the listed Company (RMB)
328800560.24 248800655.88 32.15%
Net profit attributable to shareholders of
the listed company after deducting
non-recurring gains and losses (RMB)
321593612.98 241724850.95 33.04%
Net cash flows from operating activities
(RMB)
-306748999.24 -688273848.63 55.43%
Basic earnings per share (RMB/Share) 0.77 0.58 32.76%
Diluted earnings per share (RMB/Share) 0.77 0.58 32.76%
Weighted average ROE 2.33% 1.92% 0.41 percentage point up
At the end of the reporting
period
At the end of last year
Changes of this period-end
over same period-end of last
year
Total assets (RMB) 43020753415.92 39594533471.65 8.65%
Net assets attributable to shareholder of
listed company (RMB)
14277162387.04 13948322652.33 2.36%
Items of non-recurring gains and losses
√ Applicable □ Not applicable
In RMB
Item
Amount from year-begin to
period-end
Note
Gains/losses from the disposal of non-current asset (including the
write-off that accrued for impairment of assets) 216388.08
The gains of disposal of the
right-of-use assets from store
lease surrender and the loss from
fixed assets scrapping
Governmental subsidy reckoned into current gains/losses (not
including the subsidy enjoyed in quota or ration according to
national standards which are closely relevant to enterprise’s
business)
9265003.74
Various special subsidies and tax
rebates received in the Period
Switch back of provision for depreciation of account receivable
and contract assets that are individually tested for impairment 78530.15
Other non-operating income and expenditure except for the
aforementioned items 5180996.84
The non-operating income arising
from written off the money not
required to be paid
Other gains/losses satisfy a definition of extraordinary
gains/losses 609647.62
Less: Impact on income tax 3348453.94
Impact on minority shareholders’ equity (post-tax) 4795165.23
Total 7206947.26 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss explain reasons
□ Applicable √ Not applicable
In reporting period the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss
II. Total number of shareholders at the end of this report period and top ten shareholders
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In shares
Total common shareholders at the
end of report period
42431
Total preference shareholders with
voting rights recovered at end of
reporting period (if applicable)
0
Top ten shareholders
Shareholder’s
name
Nature of
shareholder
Proportion of
shares held
Amount of shares
held
Amount of
restricted shares
held
Number of share pledged/frozen
State of share Amount
Sinopharm Group
Co. Ltd.
State-owned legal
person
56.06% 239999991 5505770
Hong Kong
Securities
Clearing
Company Ltd
Foreign
Corporation
3.55% 15215743
FIRST SENTIER
INVESTORS
GLOBAL
UMBRELLA
Foreign
Corporation
2.68% 11469644
FUND PLC -
FSSACHINA
GROWTH
FUND
China National
Pharmaceutical
Foreign Trade
Corp.
State-owned legal
person
1.24% 5323043
National Social
Security Fund-
portfolio 413
Domestic non
state-owned
Corporation
0.97% 4161032
Central Huijin
Investment Ltd.State-owned legal
person
0.89% 3804400
BBH BOS S/A
FIDELITY FD -
CHINA FOCUS
FD
Foreign
Corporation
0.78% 3358761
CPIC Fund-
China Pacific
Life Insurance
Co. Lt. -
participating
insurance -CPIC
fund PICC Stock
Relative Income
(guaranteed
bonus)single
asset
management plan
Domestic non
state-owned
Corporation
0.66% 2822801
Fidelity
Investment
Management
(Hong Kong)
Limited - Client’s
fund
Foreign
Corporation
0.54% 2308237
China
Construction
Bank Co. Ltd. -
China Europe
Value Discovery
Equity Fund
Domestic non
state-owned
Corporation
0.45% 1921921
Top ten shareholders with unrestricted shares held
Shareholder’s name Amount of unrestricted shares held Type of shares
Type Amount
Sinopharm Group Co. Ltd. 234494221
RMB ordinary
shares
234494221
Hong Kong Securities Clearing
Company Ltd
15215743
RMB ordinary
shares
15215743
FIRST SENTIER INVESTORS
GLOBAL UMBRELLA FUND PLC
- FSSA CHINAGROWTH FUND
11469644
Domestic listed
foreign shares
11469644
China National Pharmaceutical
Foreign Trade Corp.
5323043
RMB ordinary
shares
5323043
National Social Security Fund-
portfolio 413
4161032
RMB ordinary
shares
4161032
Central Huijin Investment Ltd. 3804400
RMB ordinary
shares
3804400
BBH BOS S/A FIDELITY FD -
CHINA FOCUS FD
3358761
Domestic listed
foreign shares
3358761
CPIC Fund- China Pacific Life
Insurance Co. Lt. - participating
insurance -CPIC fund PICC Stock
Relative Income (guaranteed
bonus)single asset management plan
2822801
RMB ordinary
shares
2822801
Fidelity Investment Management
(Hong Kong) Limited - Client’s fund
2308237
RMB ordinary
shares
2308237
China Construction Bank Co. Ltd. -
China Europe Value Discovery
Equity Fund
1921921
RMB ordinary
shares
1921921
Explanation on associated
relationship among the aforesaid
shareholders
Sinopharm Group Co. Ltd. and China National Pharmaceutical Foreign Trade Corporation
have the same actual controller which is China National Pharmaceutical Group Corporation.It is unknown that there exists no associated relationship or belongs to the consistent actionist
among the other tradable shareholders regulated by the Management Measure of Information
Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The top ten common shareholders or top ten common shareholders with un-restrict shares held of the Company have no buy-back
agreement dealing in reporting period.
2. Total shareholders with preferred stock held at Period-end and shares held by top ten shareholders with
preferred stock held
□Applicable √ Not applicable
Section III. Significant Events
I. Particulars about material changes in items of main accounting statement and financial
index and explanations of reasons
√Applicable □Not applicable
1.Receivable financing: a decrease of 973.0057 million Yuan compared with the beginning of the period with a growth rate of
-69.25% mainly because the bank acceptance bill discount in the Period increased;
2. Short-term borrowings: an increase of 2335.6654 million Yuan compared with the beginning of the period with a growth rate of
144.88% mainly because the supply chain financing increased in the Period;
3. Employee benefits payable: a decrease of 115.9978 million Yuan compared with the beginning of the period with a growth rate of
-32.47% mainly because the salaries and bonus accrued in the previous year are paid in the Period;
4. Other payables: an increase of 499.6124 million Yuan compared with the beginning of the period with a growth rate of 31.24%
mainly due to the equity consideration payable arising from acquisition of Yunnan Guoda Disheng Drugstore Chain Co. Ltd and
Yunnan Guoda Disheng Pharmacy Co. ltd by subsidiary of the company -Sinopharm Holding Guoda Drugstore Co. Ltd. (hereinafter
referred to as Guoda Drugstore) and the factoring return of unrecoverable account receivable increased in the Period;
5. Finance costs: an increase of 21.6634 million Yuan on a year-on-year basis with a growth rate of 74.67% mainly because paying a
large amount of equity acquisition consideration in 2020 resulting in a reduction in bank deposit and the interest from bank deposit
declined correspondingly and the interest expenses on supply chain financing increased on a y-o-y basis;
6. Investment income: an increase of 48.6294 million Yuan on a year-on-year basis with a growth rate of 113.95% mainly because
the investment income from associated enterprise increased from a year earlier;
7. Impairment losses: an increase of 1.8901 million Yuan on a year-on-year basis with a growth rate of 118.24% mainly because
provision for falling price of inventories increased on a y-o-y basis;
8. Gain on disposal of assets: an increase of 0.5332 million Yuan on a year-on-year basis with a growth rate of 204.07% mainly due
to the gains of disposal of the right-of-use assets from retail store lease surrender;
9. Non-operating income: an increase of 4.5591 million Yuan on a year-on-year basis with a growth rate of 251.64% mainly because
written off the money not required to be paid in the Period;
10. Non-operating expenses: a decrease of 1.1396 million Yuan on a year-on-year basis with a growth rate of -66.63% mainly
because the amercement outlay declined in the Period;
11. Net profit: an increase of 94.4755 million Yuan on a year-on-year basis with a growth rate of 32.02% mainly because operation
in the Period has a growth performance soaring operation income makes the gross profit increased and the investment income from
associated enterprise increased from a year earlier;
12. Profit or loss from continuing operations: an increase of 94.4755 million Yuan on a year-on-year basis with a growth rate of
32.02% mainly because operation in the Period has a growth performance soaring operation income makes the gross profit
increased and the investment income from associated enterprise increased from a year earlier;
13. Net profit attributable to owners of the parent company: an increase of 79.9999 million Yuan on a year-on-year basis with a
growth rate of 32.15 % mainly because operation in the Period has a growth performance soaring operation income makes the gross
profit increased and the investment income from associated enterprise increased from a year earlier;
14. Net profit attributable to non-controlling interests: an increase of 14.4755 million Yuan on a year-on-year basis with a growth
rate of 31.27% mainly because the subsidiary Guoda Drugstore’s net profit attributable to the owners of the parent company
increased year-on-year correspondingly the minority shareholder’s gains/losses attributable to the group’s strategic investor
Walgreens Boots Alliance (Hong Kong) Investments Limited (hereinafter referred to as "WBA") increased ;
15. Other comprehensive income net of tax: an increase of 84503.76Yuan on a year-on-year basis with a growth rate of 100.00%
mainly because other comprehensive income of associates changed during the current period;
16. Other comprehensive income attributable to shareholders of owners of the parent net of tax: an increase of 84503.76 Yuan on a
year-on-year basis with a growth rate of 100.00% mainly because other comprehensive income of associates changed during the
current period;
17. Other comprehensive income that may be reclassified to profit or loss: an increase of 84503.76 Yuan on a year-on-year basis
with a growth rate of 100.00% mainly due to the other comprehensive income available for transfer to profit/loss arising from
associates in the Period;
18. Total comprehensive income: an increase of 94.56 million Yuan on a year-on-year basis with a growth rate of 32.04% mainly
due to the relatively good operating growth in the current period gross profit increased for the soaring operation income and the
investment income from associates increased on a y-o-y basis;
19. Total comprehensive income attributable to owners of the parent: an increase of 80.0844 million Yuan on a year-on-year basis
with a growth rate of 32.19% mainly due to the relatively good operating growth in the current period gross profit increased for the
soaring operation income and the investment income from associates increased on a y-o-y basis;
20. Total comprehensive income attributable to non-controlling interests: an increase of 14.4755 million Yuan on a year-on-year basis
with a growth rate of 31.27% mainly because the net profit attributable to owners of parent company from subsidiary Guoda
Drugstore has an increased from a year earlier and correspondingly the minority shareholder’s gains/losses attributable to the group’s
strategic investor WBA increased ;
21. Basic earnings per share: an increase of 0.19 Yuan/share on a year-on-year basis with a growth rate of 32.76% mainly due to the
relatively good operating growth in the current period gross profit increased for the soaring operation income and the investment
income from associates increased on a y-o-y basis therefore the net profit attributable to shareholders of listed company increased
32.15% from a year earlier basic EPS growth correspondingly with 32.76% up;
22. Diluted earnings per share: an increase of 0.19 Yuan/share on a year-on-year basis with a growth rate of 32.76% mainly due to
the relatively good operating growth in the current period gross profit increased for the soaring operation income and the investment
income from associates increased on a y-o-y basis therefore the net profit attributable to shareholders of listed company increased
32.15% from a year earlier diluted EPS growth correspondingly with 32.76% up;
23. Receipts of taxes and surcharges refunds: an increase of 4.8427 million Yuan on a year-on-year basis with a growth rate of
624.66% mainly due to the receipt of overpaid corporate income tax rebates in previous years;
24. Other cash receipts relating to operating activities: a decrease of 223.6696 million Yuan on a year-on-year basis with a growth
rate of -51.61% mainly due to the year-on-year decrease in special reserve funds received in this period;
25. Net cash flows from operating activities: an increase of 381.5248 million Yuan on a year-on-year basis with a growth rate of
55.43% mainly due to the increase in operating income the cash received from the sale of goods and the provision of labor services
increased accordingly;
26. Cash receipts from returns of investments: an increase of 2.9974 million Yuan on a year-on-year basis with a growth rate of
100.00% mainly because the company received the withdrawal funds from the Sinopharm Zhongjin Medical Industry Fund
investment project in the period and there was no such matter in the same period last year;
27. Cash received from returns on investments: an increase of 3.5996 million Yuan on a year-on-year basis with a growth rate of
100.00% mainly because the company received dividends from Sinopharm Zhongjin Medical Industry Fund project investment in
the period and there was no such matter in the same period last year;
28. Net cash receipts from disposal of fixed assets intangible assets and other long-term assets: an increase of 0.2197 million Yuan
on a year-on-year basis with a growth rate of 204.49% mainly due to the cash received from the disposal of fixed assets increased in
the period;
29. Other cash receipts relating to investing activities: a decrease of 22 million Yuan on a year-on-year basis with a growth rate of
-100.00% mainly because at same period last year the Pudong New Area of Shanghai Pharmaceutical Medicine Ltd was combined
under the same control by the subsidiary of the company-Guoda Drugstore and recovery of the balance originally collected in the
cash pool of its original parent company while there was no such matter in the current period;
30. Total cash inflows from investing activities: a decrease of 15.1833 million Yuan on a year-on-year basis with a growth rate of
-68.68% mainly because at same period last year the Pudong New Area of Shanghai Pharmaceutical Medicine Ltd was combined
under the same control by the subsidiary of the company-Guoda Drugstore and recovery of the balance originally collected in the
cash pool of its original parent company while there was no such matter in the current period;
31. Cash payments for investments: an increase of 15.7387 million Yuan on a year-on-year basis with a growth rate of 138.78%
mainly due to the year-on-year increase in the payment of store redemption fees by Guoda Drugstore a subsidiary of the company;
32. Net cash payments for acquisition of subsidiaries and other business units: a decrease of 591.7232 million Yuan on a year-on-year
basis with a growth rate of -89.00% mainly because payment for the acquisition of the subsidiary from Guoda Drugstore in the
current period has decreased compared with the same period last year;
33. Other cash payments relating to investing activities: a decrease of 41.3645 million Yuan on a year-on-year basis with a growth
rate of -100.00% mainly because the payment of equity acquisition for previous year has been paid at same period last year while
there was no such matter in this period;
34. Total cash outflows from investing activities: a decrease of 605.5959 million Yuan on a year-on-year basis with a growth rate of
-78.87% mainly because payment for the acquisition of the subsidiary from Guoda Drugstore in the current period has decreased
compared with the same period last year;
35. Net cash flow from investment activities: an increase of 590.4126 million Yuan on a year-on-year basis with a growth rate of
79.18% mainly because payment for the acquisition of the subsidiary from Guoda Drugstore in the current period has decreased
compared with the same period last year;
36. Cash proceeds from investments by others: an increase of 5.88 million Yuan on a year-on-year basis with a growth rate of
100.00% mainly due to the receipt of investment funds from minority shareholders in this period while there was no such matter in
the same period last year;
37. Cash received from borrowing: an increase of 281.1937 million Yuan on a year-on-year basis with a growth rate of 98.25%
mainly because the bank loans received during the current period increased;
38. Total cash inflows from financing activities: an increase of 247.4363 million Yuan on a year-on-year basis with a growth rate of
39.70% mainly because the bank loans received during the current period increased;
39. Other cash payments relating to financing activities: a decrease of 227.8233 million Yuan on a year-on-year basis with a growth
rate of -48.10% mainly due to the investment amount paid for merger the Pudong New Area of Shanghai Pharmaceutical Medicine
Ltd under the same control by the subsidiary of the company-Guoda Drugstore at same period last yearwhile there was no such
matter in the current period;
40. Net cash flows from financing activities: an increase of 445.6404 million Yuan on a year-on-year basis with a growth rate of
780.23% mainly because bank loans received in the Period increased and at same period last year the investment amount are paid
for combined the Pudong New Area of Shanghai Pharmaceutical Medicine Ltd under the same control by Guoda Drugstore there
was no such matter in the current period;
41. Effect of exchange rate changes on cash and cash equivalents: a decrease of 2805.98 Yuan on a year-on-year basis with a growth
rate of -768.34% mainly due to the impact of exchange rate changes;
42. Net increase in cash and cash equivalents: an increase of 1417.5751 million Yuan on a year-on-year basis with a growth rate of
95.07% mainly due to the increase in operating income the cash received from the sale of goods and the provision of labor services
increased accordingly; and the payment for subsidiary acquisition from subsidiary Guoda Drugstore declined from a year earlier.
43. Cash and cash equivalents at beginning of the year: a decrease of 3020.9579 million Yuan on a year-on-year basis with a growth
rate of -35.85% mainly because the company paid a large amount of equity purchase consideration in 2020 resulting in a decrease in
the balance of cash and cash equivalents at the beginning of the year.II. Analysis and explanation of significant events and their influence and solutions
□Applicable √Not applicable
Progress of shares buy-back
□Applicable √Not applicable
Implementation progress of the reduction of repurchases shares by centralized bidding
□Applicable √Not applicable
III. Commitments completed in Period and those without completed till end of the Period
from actual controller shareholders related parties purchaser and companies
□Applicable √ Not applicable
The Company has no commitments completed in Period and those without completed till end of the Period from actual controller
shareholders related parties purchaser and companies.IV. Financial asset investment
1. Securities investment
□Applicable √ Not applicable
No security investment in the Period.
2. Derivative investment
□Applicable √ Not applicable
No derivative investment in the Period.V. Progress of investment projects with raised funds
□Applicable √ Not applicable
VI. Prediction of business performance from January – June 2021
Estimation on accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the
warning of its material change compared with the corresponding period of the last year and explanation on reason
□ Applicable √ Not applicable
VII. Major contracts for daily operations
□Applicable √ Not applicable
VIII. Trust financing
□Applicable √ Not applicable
No trust financing in the Period.IX. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the period.X. Non-operational fund occupation from controlling shareholders and its related party
□Applicable √ Not applicable
The Company had no non-operational fund occupation form controlling shareholders and its related party in the period.XI. Registration form for receiving research communication and interview in the report
period
□Applicable √Not applicable
The Company had no receiving research communication or interview in the report period.Section IV. Financial Statement
I. Financial Statement
1. Consolidate Balance Sheet
Prepared by China National Accord Medicines Corporation Ltd.March 31 2021
In RMB
Item March 31 2021 December 31 2020
Current assets:
Cash and bank balances 5840135730.11 5998204295.87
Settlement provisions
Capital lent
Trading financial assets
Derivative financial assets
Notes receivable 607883873.14 622115477.04
Accounts receivable 16780830492.03 13799971014.22
Receivable financing 431981996.92 1404987700.38
Advances to suppliers 590101876.56 480313574.71
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Other receivables 628399715.32 535228747.69
Including: Interest receivable
Dividend receivable
Buying back the sale of financial
assets
Inventories 7219060669.89 6285010674.46
Contract assets 15417457.50 15177731.64
Assets held for sale
Non-current asset due within one
year
Other current assets 123484117.46 121082863.45
Total current assets 32237295928.93 29262092079.46
Non-current assets:
Loans and payments on behalf
Debt investment
Other debt investment
Long-term account receivable
Long-term equity investment 2379500628.90 2287019627.99
Other equity instrument
investment
99488340.28 99488340.28
Other non-current financial assets 117974908.51 120972350.24
Investment properties 125907819.38 127444379.94
Fixed assets 843319270.30 854191083.27
Construction in progress 49119148.89 46631190.23
Productive biological asset
Oil and gas asset
Right-of-use assets 2410848611.31 2356952392.99
Intangible assets 722392930.27 734345179.40
Expense on Research and
Development
Goodwill 2975269022.11 2747375281.11
Long-term prepaid expenses 489002945.70 457705276.09
Deferred tax assets 97737555.41 92118767.81
Other non-current asset 472896305.93 408197522.84
Total non-current asset 10783457486.99 10332441392.19
Total assets 43020753415.92 39594533471.65
Current liabilities:
Short-term borrowings 3947852429.69 1612187020.12
Loan from central bank
Capital borrowed
Trading financial liability
Derivative financial liability
Notes payable 6411005653.20 7520165274.69
Accounts payable 9161357988.53 7697451142.50
Receipts in advance 10089304.61 12352466.64
Contract liabilities 382788595.61 368600357.14
Selling financial asset of
repurchase
Absorbing deposit and interbank
deposit
Security trading of agency
Security sales of agency
Employee benefits payable 241214266.47 357212047.10
Tax payable 262688620.52 316867149.16
Other payables 2098779260.44 1599166881.14
Including: Interest payable 25916885.64 35572620.82
Dividend payable 6389320.96 6389320.96
Commission charge and
commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities due within
one year
767942185.69 748732059.89
Other current liabilities 27334439.97 24787078.55
Total current liabilities 23311052744.73 20257521476.93
Non-current liabilities:
Insurance contract reserve
Long-term borrowings 31637173.89 31637173.89
Bonds payable
Including: Preferred stock
Perpetual capital
securities
Lease liabilities 1304731241.22 1303054163.90
Long-term payables 6938189.00 6938189.00
Long-term employee benefits
payable
1319000.00 1319000.00
Provisions 68808166.79 68808166.79
Deferred income 94199523.33 89843583.37
Deferred tax liabilities 201334176.46 205921408.66
Other non-current liabilities 675330586.26 740862989.59
Total non-current liabilities 2384298056.95 2448384675.20
Total liabilities 25695350801.68 22705906152.13
Owner’s equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: Preferred stock
Perpetual capital
securities
Capital surplus 4372458724.43 4372504053.72
Less: Inventory shares
Other comprehensive income 38567521.48 38483017.72
Reasonable reserve
Surplus reserve 214063491.50 214063491.50
Provision of general risk
Retained earnings 9223945666.63 8895145106.39
Total equity attributable to owners of
the parent
14277162387.04 13948322652.33
Non-controlling interests 3048240227.20 2940304667.19
Total equity 17325402614.24 16888627319.52
Total liabilities and equity 43020753415.92 39594533471.65
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Gu Guolin
Person in charge of accounting institute: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item March 31 2021 December 31 2020
Current assets:
Cash and bank balances 2918160838.33 3020909473.71
Trading financial assets
Derivative financial assets
Notes receivable 27981836.47 30984449.44
Accounts receivable 682802750.34 609575301.13
Receivables financing 18049841.43 30248631.32
Advances to suppliers 3878976.70 6722204.59
Other receivables 3762424972.63 3562309346.07
Including: Interest receivable
Dividend receivable
Inventories 217381506.64 172275777.63
Contract assets 127994.54 139154.54
Assets held for sale
Non-current assets maturing within
one year
Other current assets 39482.38 39482.38
Total current assets 7630848199.46 7433203820.81
Non-current assets:
Debt investment
Other debt investment
Long-term receivables
Long-term equity investments 7965880218.99 7873668245.16
Investment in other equity
instrument
Other non-current financial assets 117974908.51 120972350.24
Investment properties 1444115.41 1452132.04
Fixed assets 12387613.23 13279902.76
Construction in progress
Productive biological assets
Oil and natural gas assets
Right-of-use assets 4863467.72 5142755.88
Intangible assets 4687410.11 4622268.00
Research and development costs
Goodwill
Long-term deferred expenses 4102834.80 4335802.92
Deferred tax assets 9218485.21 9025057.52
Other non-current assets 12304025.21 12967715.50
Total non-current assets 8132863079.19 8045466230.02
Total assets 15763711278.65 15478670050.83
Current liabilities
Short-term borrowings 739174743.69 157892942.24
Trading financial liability
Derivative financial liability
Notes payable 295146453.96 756364719.49
Accounts payable 417332303.36 407275713.49
Accounts received in advance
Contract liabilities 8613252.72 1807562.61
Employee benefits payable 25041540.04 36672344.48
Tax payables 17831732.43 13975905.04
Other payables 3204307483.05 3167152583.28
Including: Interest payable 217961.01 170214.19
Dividend payable
Liability held for sale
Non-current liabilities due within
one year
1067368.38 1056120.58
Other current liabilities 1484550.54 636200.63
Total current liabilities 4709999428.17 4542834091.84
Non-current liabilities:
Long-term borrowings 31637173.89 31637173.89
Bonds payable
Including: preferred stock
Perpetual capital
securities
Lease liabilities 4184170.00 4455967.97
Long-term payables 800000.00 800000.00
Long term employee compensation
payable
Accrued liabilities
Deferred income 715398.06 827658.18
Deferred income tax liabilities
Other non-current liabilities 10538.58 11042.52
Total non-current liabilities 37347280.53 37731842.56
Total liabilities 4747346708.70 4580565934.40
Owners’ equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital surplus 4467946102.30 4467991431.59
Less: Inventory shares
Other comprehensive income -43529.56 -128033.32
Special reserve
Surplus reserve 214063491.50 214063491.50
Retained earnings 5906271522.71 5788050243.66
Total shareholders’ equity 11016364569.95 10898104116.43
Total liabilities and shareholders’ equity 15763711278.65 15478670050.83
3. Consolidated Profit Statement
In RMB
Item Current period Last period
I. Total operating income 16049966325.75 12824196278.66
Including: Operating revenue 16049966325.75 12824196278.66
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 15663170079.60 12488521944.35
Including: Operating cost 14260591404.46 11370970742.96
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee
slip
Reinsurance expense
Tax and surcharges 33744327.20 29109421.79
Selling expenses 1080543941.75 844624826.78
Administrative expense 237615927.36 214805866.61
R&D expense
Finance costs 50674478.83 29011086.21
Including: Interest
expense
68683688.49 60067901.98
Interest income 18058735.03 29094889.11
Add: other income 13655624.72 13133111.50
Investment income (Loss is
listed with “-”)
91305476.74 42676071.54
Including: Investment income
from associates
92441826.44 60020272.13
Income from the
derecognition of financial assets
measured at amortised cost (Loss is listed
with “-”)
-4735905.31 -18342866.43
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Credit impairment losses (Loss
is listed with “-”)
-17197080.80 -16845052.13
Impairment losses (Loss is
listed with “-”)
-3488500.85 -1598436.71
Gain on disposal of assets
(Loss is listed with “-”)
271889.26 -261264.83
III. Operating profit (Loss is listed with
“-”)
471343655.22 372778763.68
Add: Non-operating income 6370834.89 1811729.05
Less: Non-operating expense 570737.09 1710329.13
IV. Total profit 477143753.02 372880163.60
Less: Income tax expense 87580022.00 77791885.48
V. Net profit (Net loss is listed with “-”) 389563731.02 295088278.12
(i) Classify by business continuity
1. Profit or loss from continuing
operations
389563731.02 295088278.12
2.termination of net profit (net losslisted with ‘-”)
(ii) Classify by ownership
1.Net profit attributable to owners of
the parent
328800560.24 248800655.88
2. Non-controlling interests 60763170.78 46287622.24
VI. Other comprehensive income net of
tax
84503.76
Other comprehensive income
attributable to shareholders of owners of
the parent net of tax
84503.76
(i) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
that may be reclassified to profit or loss
84503.76
1. Other comprehensive
income using the equity method that may
be reclassified to profit or loss
84503.76
2.Change of fair value of
other debt investment
3.Amount of financial assets
re-classify to other comprehensive
income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging reserve
6.Translation differences
arising on translation of foreign currency
financial statements
7.Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 389648234.78 295088278.12
Total comprehensive income
attributable to owners of the parent
328885064.00 248800655.88
Total comprehensive income
attributable to non-controlling interests
60763170.78 46287622.24
VIII. Earnings per share:
(i) Basic earnings per share 0.77 0.58
(ii) Diluted earnings per share 0.77 0.58
Enterprise combine under the same control in the Period the combined party realized net profit of 0 Yuan before combination and
realized 0 Yuan at last period for combined party
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Gu Guolin
Person in charge of accounting institute: Wang Ying
4. Profit Statement of Parent Company
In RMB
Item Current period Last period
I. Operating revenue 1031796119.30 883090683.07
Less: Operating costs 991971454.23 850760365.77
Taxes and surcharge 1161587.51 1011193.50
Selling expenses 16856699.35 16302891.84
Administrative expenses 20817040.62 22374408.72
R&D expenses
Finance costs -29303964.67 -22842676.94
Including: interest expense 10689978.60 9151290.82
Interest income 40183409.94 32061791.21
Add: other income 401103.90 293056.51
Investment income (Loss is
listed with “-”)
95583979.88 60592685.27
Including: Investment income
on affiliated Company and joint venture
92172799.36 60134457.45
Income from the
derecognition of financial assets
measured at amortised cost (Loss is
listed with “-”)
-188375.09 -540438.02
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Credit impairment losses
(Loss is listed with “-”)
-973888.89
Impairment losses (Loss is
listed with “-”)
-561173.91 217422.14
Gain on disposal of assets
(Loss is listed with “-”)
22815.68
II. Operating profit (Loss is listed with
“-”)
125740027.81 75613775.21
Add: Non-operating income 1645.98 1578.11
Less: Non-operating expense
III. Total Profit (Loss is listed with “-”) 125741673.79 75615353.32
Less: Income tax expense 7520394.74 3620557.51
IV. Net profit (Net loss is listed with
“-”)
118221279.05 71994795.81
(i) Profit or loss from continuingoperations (net loss listed with ‘-”)
118221279.05 71994795.81
(ii) termination of net profit (netloss listed with ‘-”)
V. Other comprehensive income net of
tax
84503.76
(i) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
that may be reclassified to profit or loss
84503.76
1. Other comprehensive
income using the equity method that
may be reclassified to profit or loss
84503.76
2.Change of fair value of
other debt investment
3.Amount of financial
assets re-classify to other
comprehensive income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging
reserve
6.Translation differences
arising on translation of foreign
currency financial statements
7.Other
VI. Total comprehensive income 118305782.81 71994795.81
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Cash Flow Statement
In RMB
Item Current period Last period
I. Cash flows from operating activities:
Cash received from sales of good
or rendering of services
15194724502.12 13201992638.81
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings
and investment
Cash received from interest
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Net cash received by agents in sale
and purchase of securities
Receipts of taxes and surcharges
refunds
5617976.11 775261.38
Other cash receipts relating to
operating activities
209745502.46 433415062.71
Total cash inflows from operating
activities
15410087980.69 13636182962.90
Cash payments for goods and
services
14094028880.65 12827089312.11
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Net increase of capital lent
Cash paid for interest commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash payments to and on behalf of
employees
894497321.19 703922606.95
Payments of all types of taxes and 354054737.85 368976475.15
surcharges
Other cash payments relating to
operating activities
374256040.24 424468417.32
Total cash outflows from operating
activities
15716836979.93 14324456811.53
Net cash flows from operating activities -306748999.24 -688273848.63
II. Cash flows from investing activities:
Cash receipts from returns of
investments
2997441.73
Cash received from returns on
investments
3599555.61
Net cash receipts from disposal of
fixed assets intangible assets and other
long-term assets
327119.50 107430.91
Net cash received from disposal of
subsidiaries and other units
Other cash receipts relating to
investing activities
22000000.00
Total cash inflows from investing
activities
6924116.84 22107430.91
Cash payments to acquire fixed
assets intangible assets and other
long-term assets
61960648.98 50207587.50
Cash payments for investments 27079733.00 11341032.15
Net increase of mortgaged loans
Net cash payments for acquisition
of subsidiaries and other business units
73159498.29 664882681.20
Other cash payments relating to
investing activities
41364521.11
Total cash outflows from investing
activities
162199880.27 767795821.96
Net cash flows from investing activities -155275763.43 -745688391.05
III. Cash flows from financing activities
Cash proceeds from investments
by others
5880000.00
Incl: Cash receipts from capital
contributions from non-controlling
interests of subsidiaries
5880000.00
Cash receipts from borrowings 567395696.23 286202002.73
Other cash receipts relating to
financing activities
297416755.19 337054182.02
Total cash inflows from financing
activities
870692451.42 623256184.75
Cash repayments for debts 177254802.73 142100000.00
Cash payments for distribution of
dividends or profit and interest
expenses
59139307.66 64675017.27
Incl: Dividends or profit paid to
non-controlling shareholders of
subsidiaries
555825.80 1558470.71
Other cash payments relating to
financing activities
245774326.14 473597592.59
Total cash outflows from financing
activities
482168436.53 680372609.86
Net cash flows from financing activities 388524014.89 -57116425.11
IV. Effect of foreign exchange rate
changes on cash and cash equivalents
-2440.78 365.20
V. Net increase of cash and cash
equivalents
-73503188.56 -1491078299.59
Add: Cash and cash equivalents at
beginning of the year
5405113257.99 8426071170.16
VI. Cash and cash equivalents at end of
year
5331610069.43 6934992870.57
6. Cash Flow Statement of Parent Company
In RMB
Item Current period Last period
I. Cash flows from operating activities:
Cash receipts from the sale of
goods and the rendering of services
1022932449.00 1062518589.11
Write-back of tax received
Other cash receipts relating to
operating activities
14576152.93 22736474.18
Total cash inflows from operating
activities
1037508601.93 1085255063.29
Cash payments for goods and
services
1132644884.96 1207589273.35
Cash payments to and on behalf of
employees
41055249.91 39968369.74
Payments of all types of taxes and
surcharges
12594584.85 20509993.91
Other cash payments relating to
operating activities
5207747.54 14820413.79
Total cash outflows from operating
activities
1191502467.26 1282888050.79
Net cash flows from operating activities -153993865.33 -197632987.50
II. Cash flows from investing activities:
Cash receipts from returns of
investments
2997441.73 13636447.00
Cash receipts from returns on
investments
3599555.61
Net cash receipts from disposal of
fixed assets intangible assets and other
long-term assets
233663.00
Net cash received from disposal of
subsidiaries and other units
Other cash receipts relating to
investing activities
721955173.97 602709245.48
Total cash inflows from investing
activities
728785834.31 616345692.48
Cash paid for acquisition of fixed
assets intangible assets and other
long-term assets
710954.22 670760.44
Cash paid for investment
Net cash received from
subsidiaries and other units obtained
Other cash payments relating to
investing activities
895600000.00 792214521.11
Total cash outflows from investing
activities
896310954.22 792885281.55
Net cash flows from investing activities -167525119.91 -176539589.07
III. Cash flows from financing activities
Cash received from absorbing
investment
Cash receipts from borrowings 210000000.00 24694789.52
Other cash receipts relating to
financing activities
8801174486.16 8004663212.88
Total cash inflows from financing
activities
9011174486.16 8029358002.40
Cash repayments for debts 22594789.52 12100000.00
Cash payments for distribution of
dividends profit or interest expenses
10931189.66 9363675.10
Other cash payments relating to
financing activities
8758875716.34 7724025779.65
Total cash outflows from financing
activities
8792401695.52 7745489454.75
Net cash flows from financing activities 218772790.64 283868547.65
IV. Effect of foreign exchange rate
changes on cash and cash equivalents
-2440.78 365.20
V. Net increase of cash and cash
equivalents
-102748635.38 -90303663.72
Add: Cash and cash equivalents at
beginning of the year
3020909473.71 2894333956.38
VI. Cash and cash equivalents at end of
year
2918160838.33 2804030292.66
II. Explanation on financial statement adjustment
1. Financial statement adjustment at the beginning of the first year when implementation of new leasing
rules from 2021
□Applicable √Not applicable
2. Retrospective adjustment of the comparative data for initial new leasing rules from 2021
□Applicable √Not applicable
III. Audit report
Whether the 1st quarterly report has been audited or not
□Yes √ No
1Q report of the Company is unaudited.
China National Accord Medicines Corporation Ltd.
Legal Representative: Lin Zhaoxiong
24 April 2021
沪公网安备31011802005267号
